Assaf A Barg1,2, Sarah Malkiel1,2, Maya Bartuv3, Gahl Greenberg4, Amos Toren1,2, Nathan Keller5,6. 1. Department of Pediatric Hematology, Oncology & BMT, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Pharmacy Services, Sheba Medical Center, Ramat-Gan, Israel. 4. Department of Diagnostic imaging, Sheba Medical Center, Ramat-Gan, Israel. 5. Pediatric Infectious Disease Unit, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel. 6. The Department of Health Management, Ariel University, Ariel, Israel.
Abstract
BACKGROUND: Invasive mold infections (IMIs) are a leading cause of mortality among immunocompromised patients. Isavuconazole is a new drug that shows promise in the adult population for the treatment of IMIs. No data regarding the use of isavuconazole in pediatric patients have been published. METHODS: Patients with a diagnosis of IMI from our pediatric hemato-oncology division, treated with isavuconazole between 2010 and 2016, were identified using the hospital's computerized database. Data including demographics, clinical course, and outcome were collected. Pharmacokinetic samples were obtained from two younger patients to guide dosing. RESULTS: In total, three patients (4.5, 5, and 19 years of age) with invasive mucormycosis who were treated with isavuconazole were identified. All patients were treated with isavuconazole as a second line therapy and experienced improvement following the initiation of this treatment. CONCLUSIONS: Based on our limited clinical experience, isavuconazole may be a safe and effective treatment option for children and adolescents afflicted by IMI. Prospective clinical trials should be performed in order to evaluate the pharmakokinetics and safety of isavuconazole in the pediatric population.
BACKGROUND: Invasive mold infections (IMIs) are a leading cause of mortality among immunocompromised patients. Isavuconazole is a new drug that shows promise in the adult population for the treatment of IMIs. No data regarding the use of isavuconazole in pediatric patients have been published. METHODS:Patients with a diagnosis of IMI from our pediatric hemato-oncology division, treated with isavuconazole between 2010 and 2016, were identified using the hospital's computerized database. Data including demographics, clinical course, and outcome were collected. Pharmacokinetic samples were obtained from two younger patients to guide dosing. RESULTS: In total, three patients (4.5, 5, and 19 years of age) with invasive mucormycosis who were treated with isavuconazole were identified. All patients were treated with isavuconazole as a second line therapy and experienced improvement following the initiation of this treatment. CONCLUSIONS: Based on our limited clinical experience, isavuconazole may be a safe and effective treatment option for children and adolescents afflicted by IMI. Prospective clinical trials should be performed in order to evaluate the pharmakokinetics and safety of isavuconazole in the pediatric population.
Authors: N Decembrino; K Perruccio; M Zecca; A Colombini; E Calore; P Muggeo; E Soncini; A Comelli; M Molinaro; B M Goffredo; S De Gregori; I Giardini; L Scudeller; S Cesaro Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: Stefan Schwartz; Oliver A Cornely; Kamal Hamed; Francisco M Marty; Johan Maertens; Galia Rahav; Raoul Herbrecht; Werner J Heinz Journal: Med Mycol Date: 2020-06-01 Impact factor: 4.076
Authors: Philippe Zimmermann; Benoit Brethon; Julie Roupret-Serzec; Marion Caseris; Lauriane Goldwirt; André Baruchel; Marie de Tersant Journal: Pharmaceuticals (Basel) Date: 2022-03-19